So far, several HDAC inhibitors have undergoneclinical trials, with five receiving FDA approval for cancer treatments(vorinostat, panobinostat, romidepsin, and belinostat) and for thetreatment of Duchenne muscular dystrophy (givinostat). Here, HDAC9 is linked to Duchenne muscular dystrophy.